1,463 results on '"Maeda A"'
Search Results
2. Whole-genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in adult T-cell leukemia/lymphoma
3. Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas
4. Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma
5. Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2-rearranged Ph-like ALL
6. Real-World Data in a Prospective Clinical Observation Study for Newly Diagnosed Adult Acute Lymphoblastic Leukemia, the JALSG ALL-CS-12 : Advanced Age Is a Poor Prognostic Factor
7. CELMoD for ALL: an exciting prospect
8. Identification of unipotent megakaryocyte progenitors in human hematopoiesis
9. PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy
10. Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas
11. Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms
12. Poor Prognostic Combination of Additional Chromosomal Abnormalities in Ph + ALL : JALSG Ph+ALL TKI- SCT Study
13. Clinical Impact of Cell-of-Origin and Double-Hit Signature of DLBCL in Japan
14. Phase 1 Results of the First-in-Class CXCR1/2 Inhibitor SX-682 in Patients with Hypomethylating Agent Failure Myelodysplastic Syndromes
15. α-Mannan induces Th17-mediated pulmonary graft-versus-host disease in mice
16. Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma
17. Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2-rearranged Ph-like ALL
18. Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma
19. Impact of the Dose of Post-Transplant Cyclophosphamide and the Start Timing of Tacrolimus in Patients Who Received Allogeneic Stem-Cell Transplantation from Haploidentical Donor
20. Phase 1 Results of the First-in-Class CXCR1/2 Inhibitor SX-682 in Patients with Hypomethylating Agent Failure Myelodysplastic Syndromes
21. Poor Prognostic Combination of Additional Chromosomal Abnormalities in Ph + ALL : JALSG Ph+ALL TKI- SCT Study
22. The XPO7/Npat Axis Is a Potential Therapeutic Target for TP53-Mutated AML
23. A Genome-Wide CRISPR-Cas9 Screen Reveals GATOR1 Complex Is a Critical Regulator of Glucocorticoid Sensitivity in B-Cell Precursor Acute Lymphoblastic Leukemia
24. Improving Prognosis of Aggressive Natural Killer Cell Leukemia in Japan
25. Clinical Impact of Cell-of-Origin and Double-Hit Signature of DLBCL in Japan
26. Influence of Oral Microbiota on Chronic Graft-Versus-Host Disease and Its Role As a Therapeutic Target
27. Gilteritinib Maintenance Therapy Post-Allogenic Stem-Cell Transplantation Improves the Prognosis of Patients with FLT3-Mutated AML
28. Prognostic Impact of Chromosomal Abnormalities in TP53-Mutated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
29. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia
30. Role of LRF/Pokemon in lineage fate decisions
31. Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma
32. Impact of the Dose of Post-Transplant Cyclophosphamide and the Start Timing of Tacrolimus in Patients Who Received Allogeneic Stem-Cell Transplantation from Haploidentical Donor
33. Gilteritinib Maintenance Therapy Post-Allogenic Stem-Cell Transplantation Improves the Prognosis of Patients with FLT3-Mutated AML
34. Improving Prognosis of Aggressive Natural Killer Cell Leukemia in Japan
35. Influence of Oral Microbiota on Chronic Graft-Versus-Host Disease and Its Role As a Therapeutic Target
36. The transcription factor Spi-B regulates human plasmacytoid dendritic cell survival through direct induction of the antiapoptotic gene BCL2-A1
37. Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma
38. Synthetic retinoid Am80 ameliorates chronic graft-versus-host disease by down-regulating Th1 and Th17
39. Aromatase is a novel neosubstrate of cereblon responsible for immunomodulatory drug–induced thrombocytopenia
40. Vitamin C is dispensable for oxygen sensing in vivo
41. Critical role of transcription factor PU.1 in the expression of CD80 and CD86 on dendritic cells
42. Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis
43. A Genome-Wide CRISPR-Cas9 Screen Reveals GATOR1 Complex Is a Critical Regulator of Glucocorticoid Sensitivity in B-Cell Precursor Acute Lymphoblastic Leukemia
44. Hepatic toxicity and prognosis in hepatitis C virus–infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis
45. E-selectin engages PSGL-1 and CD44 through a common signaling pathway to induce integrin αLβ2-mediated slow leukocyte rolling
46. IL-6 increases B-cell IgG production in a feed-forward proinflammatory mechanism to skew hematopoiesis and elevate myeloid production
47. Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma
48. Genome-Wide CRISPR-Cas9 Screen Identifies Rationally Designed Combination Therapies Relevant for CRLF2-Rearranged Ph-like ALL
49. Outcomes of Transplant-Eligible Patients with Myelodysplastic Syndrome-Refractory Anemia with Excess Blasts Registered in a Prospective Observational Study: The JALSG-CS11-MDS-SCT
50. KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.